WO2000053581A2 - Composes heterocycliques ayant une activite antitumorale - Google Patents

Composes heterocycliques ayant une activite antitumorale Download PDF

Info

Publication number
WO2000053581A2
WO2000053581A2 PCT/EP2000/001721 EP0001721W WO0053581A2 WO 2000053581 A2 WO2000053581 A2 WO 2000053581A2 EP 0001721 W EP0001721 W EP 0001721W WO 0053581 A2 WO0053581 A2 WO 0053581A2
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
dihydrofuran
compounds
formula
phenyl
Prior art date
Application number
PCT/EP2000/001721
Other languages
English (en)
Other versions
WO2000053581A3 (fr
Inventor
Ernesto Menta
Marco Conti
Nicoletta Pescalli
Original Assignee
Novuspharma S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novuspharma S.P.A. filed Critical Novuspharma S.P.A.
Priority to JP2000604021A priority Critical patent/JP2002539114A/ja
Priority to EP00920458A priority patent/EP1173420A2/fr
Priority to AU41033/00A priority patent/AU4103300A/en
Publication of WO2000053581A2 publication Critical patent/WO2000053581A2/fr
Publication of WO2000053581A3 publication Critical patent/WO2000053581A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Definitions

  • the present invention relates to heterocyclic compounds having antitumor activity, in particular against solids tumors, specifically colon tumors.
  • carcinoma of the colon and rectum is a very common tumor in Western countries, in that it has an incidence of about 421,000 new cases each year in the world and is second only to lung and breast tumors as cause of death.
  • the percentage of patients which can be treated surgically is about 45-50%, the remaining patients being treated with combined chemotherapy, to obtain a complete remission percentage not above 5%.
  • Tumors of the colon and rectum are usually refractory or poorly sensitive to chemotherapy available at present and the only effective agent to some extent against this type of cancer is 5-fluorouracil .
  • EP-A- 997115391.1 discloses a novel class of compounds with antitumor activity particularly against colon tumors.
  • Said compounds are 4-ureido and thioureido derivatives of 2 (5H) -furanone or 2 (5H) -thiophenone .
  • the present invention relates to novel heterocyclic compounds having antitumor activity in particular against colon tumors, having the following general formula (I) in which:
  • R is C ⁇ _- ] _oalkyl, C3 _7cycloalkyl , C 7 _ 14 arylalkyl , naphthyl, phenyl optionally mono- or poly- substituted, 5 or 6 membered aromatic or non aromatic heterocyclic ring, optionally benzocondensed;
  • aryl group is a phenyl optionally substituted with one or two methoxy groups.
  • R is a heterocyclic ring
  • this is preferably selected from the group consisting of pyridine, pyrrole, thiazole, thiophene, furan, imidazole, pyrazine, pyrimidine, quinoline, isoquinoline, indole, 3 , 4-methylenedioxyphenyl , piperazine, piperidine, morpholine and pyrrolidine.
  • R is a mono- or poly- substituted phenyl
  • preferred substituents are C ⁇ __ 4 alkyl, in particular ethyl, C__3polyhaloalkyl , in particular, trifluoromethyl , and halogen, in particular chlorine.
  • a preferred group of compounds of formula (I) is the one in which n is 0, Y is NH, R ⁇ _ and R 2 are hydrogen, R is a substituted phenyl and the dotted line means a bond.
  • Another group of preferred compounds of formula (I) is the one in which n is 0, Y is oxygen, X is -NH-CO-NH-, R is phenyl substituted with one or more groups selected from
  • R ⁇ _ is -CH 2 -NR a R ]3 , wherein R a and R j -- are as defined above and the dotted line is a bond.
  • the present invention further relates to pharmaceutical formulations containing a pharmaceutically effective amount of one or more compounds of formula (I) in mixture with pharmaceutically acceptable excipients .
  • Another object of the invention is to provide processes for the preparation of the compounds of formula (I) .
  • the compounds of formula (I) in which the dotted line means a bond and which have an -NH- group at the 4- position of formula (I) can be prepared by reacting a compound of formula (II)
  • n, Y, R ⁇ _ and R 2 are as defined for compounds o formula (I) , with a compound of formula (III)
  • the reaction is generally carried out in solution, operating in a solvent such as an alcohol (methanol, ethanol, propanol or butanol) or an aromatic hydrocarbon (benzene, toluene, xylene) under reflux or at 50-150°C, preferably 80- 120°C.
  • a solvent such as an alcohol (methanol, ethanol, propanol or butanol) or an aromatic hydrocarbon (benzene, toluene, xylene) under reflux or at 50-150°C, preferably 80- 120°C.
  • the reaction can also be carried out either without solvent or with a small amount of a high boiling solvent, such as toluene, xylene, dioxane, dimethylformamide, nitromethane or n-butanol, if necessary to obtain a clear molten mass.
  • a small amount of a Lewis acid such as p-toluenesulfonic acid, can be optionally used.
  • the compounds of formula (I) in which the dotted line means a bond and X is -NH-CO-NH-CO- or -NH-CO-NH-S0 2 - are preferably obtained by reacting a compound of formula (II 1 )
  • the reaction is generally carried out in an inert solvent, such as tetrahydrofuran, dimethoxyethane, dioxane, toluene, xylene, at temperatures ranging from 0°C to the reflux temperature of the solvent, preferably 20-50°C.
  • an inert solvent such as tetrahydrofuran, dimethoxyethane, dioxane, toluene, xylene
  • the reaction is generally carried out in an inert solvent such as tetrahydrofuran, 1 , 2-dimethoxyethane, dioxane, toluene, xylene, dichloromethane , at a temperature ranging from -20°C to the reflux temperature of the solvent, preferably at 0-40°C, in the presence of at least one molar equivalent of an inorganic or organic base, such as, for example, alkaline or alkaline-earth metal carbonates or bicarbonates , or tertiary amines such as triethylamine or pyridine and the like.
  • an inert solvent such as tetrahydrofuran, 1 , 2-dimethoxyethane, dioxane, toluene, xylene, dichloromethane
  • an inorganic or organic base such as, for example, alkaline or alkaline-earth metal carbonates or bicarbonates , or tertiary amines such as
  • Hal is halogen and R3 is C ⁇ __3al yl, by heating them in a solvent .
  • n, Y, R ] _ and R 2 are as defined for compounds of formula (I) , with a compound of formula (VI)
  • the compounds of formula (I) in which the dotted line means no bond can be obtained starting from the corresponding unsaturated compounds of formula (I) by chemical or catalytic reduction.
  • the compounds of formula (I) in which R_ is a group of formula [CH 2 ) p -A, wherein p is different from 1 and A is different from OH or NR a R b , are prepared by reacting dicarbonyl compound of formula (II) in which R]_ is H with a compound of formula T-(CH 2 ) p -A, in which T is a leaving group, for example halogen, followed by reaction with a compound of formula W-NH 2 (III), according to the following scheme.
  • the compounds according to the invention were pharmacologically tested against human tumor cell lines: HT 29 (colon carcinoma) , PC 3 (prostate carcinoma) , H 460M (lung carcinoma) , MCF-7 (breast carcinoma) .
  • Cells were incubated for 144 hour with the tested compound, then cytotoxicity was determined using the MTT test (Mosman, T. "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay”; J. Immunolog. Methods, (1983), 65, 66; Green, L.M., “Rapid Colorimetric Assay for Cell Viability; Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines” , J. Immunol. Methods, (1984) , 70, 257-268) .
  • the obtained data showed that the compounds of the present invention have a marked activity against solid tumors, in particular colon tumors.
  • the compounds of the invention can be administered in doses ranging from 0.01 mg to 0.4 g/Kg body weight daily.
  • a preferred administration procedure is that using a dosage from about 1 mg to about 50 mg/Kg body weight daily, using such unitary doses as to administer in 24 hours from about 70 mg to about 3.5 g of the active substance to a patient of about 70 Kg.
  • Such administration procedure can be adjusted to obtain a better therapeutical effect.
  • doses can be adjusted according to the therapeutical conditions of the patient.
  • the active compounds of the invention can be administered through the oral, intravenous, intramuscular or subcutaneous routes .
  • compositions of the invention contain therapeutically effective amounts of at least one compound of the invention in mixture with excipients compatible with the pharmaceutical use.
  • compositions for the oral route generally comprise an inert diluent or an edible carrier and can be in the form of gelatin capsules or tablets.
  • Other possible oral administration forms are capsules, pills, elixirs, suspensions or syrups .
  • Tablets, pills, capsules and similar compositions can contain the following ingredients (in addition to the active compound) : a ligand, such as microcrystalline cellulose, tragacanth or gelatin; a carrier such as starch or lactose, a disintegrant such as alginic acid, primogel, maize starch and the like; a lubrificant such as magnesium stearate; a fluidifying agent such as colloidal silicon dioxide; a sweetener such as saccharose or saccharin or a flavoring agent such as mint flavor, methyl salicylate or orange flavor.
  • a liquid carrier such as a fat oil.
  • Other compositions can contain various materials, for example coating agents (for tablets and pills) such as sugar or shellac. The material used in the preparation of the compositions should be pharmaceutically pure and non toxic at the used dosages.
  • the active ingredient can be included in solutions or suspensions, which can further contain the following components: a sterile diluent such as water for injections, saline solution, oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvents; antibacterials such as benzyl alcohol; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffering agents such as acetates, citrates or phosphates and tonicity agents, such as sodium chloride or dextrose.
  • a sterile diluent such as water for injections, saline solution, oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvents
  • antibacterials such as benzyl alcohol
  • antioxidants such as ascorbic acid or sodium bisulfite
  • chelating agents such as ethylenediaminetetraacetic acid
  • buffering agents such as acetates, cit
  • aqueous solution is adjusted to pH 9 with 20% NaOH and extracted with ethyl acetate (2 x 50 ml) .
  • the combined organic phases are dried and concentrated to dryness, to give a residue which is purified by column chromatography (silica; eluent ethyl acetate) to give 4- (3 -chloro-4 -ethylphenyl) semicarbazide (277 mg) which is used without further purification.
  • Preparation 2 4-chlorophenylacetamide A suspension of 4-chlophenylacetic acid (1.7 g) in thionyl chloride (5 ml) is stirred at room temperature for 3 hours. The thionyl chloride excess is distilled off under vacuum, keeping the temperature below 30°C. The residue is taken up into toluene and the solvent is distilled off under vacuum. This operation is repeated three times. After completion, the residue is dissolved in THF (50 mL) and ammonia is bubbled through the solution, keeping the temperature at about 10 °C. The resulting suspension is diluted with water to give a clear solution which is concentrated to small volume. The precipitate is recovered by filtration and washed on the filter with water/THF 7/3, to give
  • Example 13 4- (5-oxo-2 , 5-dihydrofuran-3-yl) -1-phenylsemicarbazide

Abstract

L'invention concerne des composés de formule générale (I), dans laquelle Y est O, S ou NH; n est 0 ou 1; X est choisi dans le groupe formé de NH-CO-NH, -NH-CO-, NH-SO2-, -NH-, -CO-NH-, -CO-NH-NH-, -NH-NH-CO-, -NH-NH-SO2-, -NH-CO-CO-, -NH-CO-CH2-, -NH-NH-, -NH-NH-CO-NH-, -NH-CO-NH-NH-, -NH-CO-NH-NH-, -CO-, -NH-SO2-NH-, -CO-NH-CO-NH-, -NH-CO-NH-CO-, -NH-CO-NH-SO2-, -NH-C(=NH)-NH-NH-, -NH-NH-C(=NH)-NH-, -CH=CH-, -CO-CH=CH-, -CH=CH-CO-, cyclopropane-1,2-di-yle, -NH-CH(COORC)-; R1 est choisi dans le groupe formé de H, alkyle, -(CH2)p-A, dans lequel p = 0-4 et A =OH, -NRaRb, -COORc, -CONRaRb, -CONH(CH2)q-NRaRb, -CONH(CH2)q-COORc, où q = 1-4, Ra et Rb sont H, alkyle, ou Ra et Rb ainsi que l'atome d'azote sont liés pour former un noyau hétérocyclique à 4-7 éléments; Rc est H, alkyle ou alcali ou un métal alcalino-terreux; R est alkyle, cycloalkyle, arylalkyle, naphtyle, phényle facultativement substitué, un noyau hétérocyclique aromatique ou non aromatique à 5 ou 6 éléments facultativement benzocondensé; R2 est H ou alkyle et le pointillé représente une liaison facultative, que l'on peut utiliser comme médicaments, en particulier comme agents antitumoraux.
PCT/EP2000/001721 1999-03-05 2000-03-01 Composes heterocycliques ayant une activite antitumorale WO2000053581A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000604021A JP2002539114A (ja) 1999-03-05 2000-03-01 抗腫瘍活性を有する複素環化合物
EP00920458A EP1173420A2 (fr) 1999-03-05 2000-03-01 Composes heterocycliques ayant une activite antitumorale
AU41033/00A AU4103300A (en) 1999-03-05 2000-03-01 Heterocyclic compounds having antitumor activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI99A000456 1999-03-05
IT1999MI000456A IT1309593B1 (it) 1999-03-05 1999-03-05 Composti eterociclici ad attivita' antitumorale.

Publications (2)

Publication Number Publication Date
WO2000053581A2 true WO2000053581A2 (fr) 2000-09-14
WO2000053581A3 WO2000053581A3 (fr) 2000-12-21

Family

ID=11382169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001721 WO2000053581A2 (fr) 1999-03-05 2000-03-01 Composes heterocycliques ayant une activite antitumorale

Country Status (5)

Country Link
EP (1) EP1173420A2 (fr)
JP (1) JP2002539114A (fr)
AU (1) AU4103300A (fr)
IT (1) IT1309593B1 (fr)
WO (1) WO2000053581A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168649B2 (en) 2005-06-28 2012-05-01 Merk Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CN109651310A (zh) * 2018-12-26 2019-04-19 华南师范大学 一种n-呋喃酮基芳基磺酰肼类衍生物及其制备方法和应用
EP3599234A1 (fr) 2015-09-18 2020-01-29 Boehringer Ingelheim International GmbH Procédé stéréosélectif
CN113980004A (zh) * 2021-10-18 2022-01-28 成都大学 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
DE2108926A1 (en) * 1971-02-25 1972-08-31 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen 3-acyl-4-hydroxy-2-butenoic acid lactone prepn - from an alpha-ketocarboxylic acid and an alpha beta unsatd carbonyl cpd
EP0560389A1 (fr) * 1992-03-13 1993-09-15 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Lactone possédant une activité immunosuppréssive
WO1996040673A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Nouveaux composes de type uree et thiouree
EP0841063A1 (fr) * 1996-03-27 1998-05-13 Toray Industries, Inc. Derives de cetone et usage medicinal
WO1999012917A1 (fr) * 1997-09-05 1999-03-18 Roche Diagnostics Gmbh Derives d'ureido et thioureido de 4-amino-2(5h)-furanones et 4-amino-2(5h)-thiophenones en tant qu'agents anti-tumoraux

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
DE2108926A1 (en) * 1971-02-25 1972-08-31 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen 3-acyl-4-hydroxy-2-butenoic acid lactone prepn - from an alpha-ketocarboxylic acid and an alpha beta unsatd carbonyl cpd
EP0560389A1 (fr) * 1992-03-13 1993-09-15 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Lactone possédant une activité immunosuppréssive
WO1996040673A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Nouveaux composes de type uree et thiouree
EP0841063A1 (fr) * 1996-03-27 1998-05-13 Toray Industries, Inc. Derives de cetone et usage medicinal
WO1999012917A1 (fr) * 1997-09-05 1999-03-18 Roche Diagnostics Gmbh Derives d'ureido et thioureido de 4-amino-2(5h)-furanones et 4-amino-2(5h)-thiophenones en tant qu'agents anti-tumoraux

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HIYAMA T ET AL: "SYNTHESIS OF 4-AMINO-2(5H)-FURANONES THROUGH INTRA- AND INTERMOLECULAR NITRILE ADDITION OF ESTER ENOLATES. CONTRICTION OF CARBON FRAMEWORK OF AN ANTITUMOR ANTIBIOTIC BASIDALIN" BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN,JP,JAPAN PUBLICATIONS TRADING CO. TOKYO, vol. 60, no. 6, 1 June 1987 (1987-06-01), pages 2139-2150, XP002053923 ISSN: 0009-2673 cited in the application *
K.-B. WALTER ET AL.: "Stickstoffhaltige Derivate der Tetrons{ure" ARCHIV DER PHARMAZIE., vol. 320, 1987, pages 749-755, XP000946110 VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM., DE ISSN: 0365-6233 cited in the application *
MEULDERMANS W ET AL: "EXCRETION AND BIOTRANFORMATION OF CISAPRIDE IN RATS AFTER ORAL ADMINISTRATION" DRUG METABOLISM AND DISPOSITION,US,WILLIAMS AND WILKINS., BALTIMORE, MD, vol. 16, no. 3, 1 May 1988 (1988-05-01), pages 410-419, XP000577692 ISSN: 0090-9556 *
MEULDERMANS W ET AL: "EXCRETION AND BIOTRANSFORMATION OF CISAPRIDE IN DOGS AND HUMANS AFTER ORAL ADMINISTATION" DRUG METABOLISM AND DISPOSITION,US,WILLIAMS AND WILKINS., BALTIMORE, MD, vol. 16, no. 3, 1 May 1988 (1988-05-01), pages 403-409, XP000577694 ISSN: 0090-9556 *
R. J. CAPON ET AL.: "Synthesis of the Thermolysis Product of 6beta-Hydroxyaplystatin" JOURNAL OF CHEMICAL RESEARCH (S), 1987, pages 118-119, XP000946119 cited in the application *
T. MOMOSE ET AL.: "2(3H)- and 2(5H)-Furanones. III. An Efficient Synthesis and the Eschenmoser-Mannich Reaction of N-substituted 4-Amino-2(5H)-furanones" HETEROCYCLES., vol. 27, no. 8, 1988, pages 1907-1923, XP000946112 AMSTERDAM NL cited in the application *
Y. MORISHITA ET AL.: "Regressive Effects of Various Chemopresentive Agents on Azoxymethane-induced Aberrant Crypt Foci in the Rat Colon" JAPANESE JOURNAL OF CANCER RESEARCH, vol. 88, no. 9, 1997, pages 815-820, XP000946118 cited in the application *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168649B2 (en) 2005-06-28 2012-05-01 Merk Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP3599234A1 (fr) 2015-09-18 2020-01-29 Boehringer Ingelheim International GmbH Procédé stéréosélectif
CN109651310A (zh) * 2018-12-26 2019-04-19 华南师范大学 一种n-呋喃酮基芳基磺酰肼类衍生物及其制备方法和应用
CN109651310B (zh) * 2018-12-26 2022-07-22 华南师范大学 一种n-呋喃酮基芳基磺酰肼类衍生物及其制备方法和应用
CN113980004A (zh) * 2021-10-18 2022-01-28 成都大学 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法
CN113980004B (zh) * 2021-10-18 2023-07-04 成都大学 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法

Also Published As

Publication number Publication date
WO2000053581A3 (fr) 2000-12-21
ITMI990456A1 (it) 2000-09-05
EP1173420A2 (fr) 2002-01-23
IT1309593B1 (it) 2002-01-24
AU4103300A (en) 2000-09-28
JP2002539114A (ja) 2002-11-19

Similar Documents

Publication Publication Date Title
EP0674624B1 (fr) Pyrazoles presentant une activite d'antagonistes du facteur de liberation de la cortitrophine
EP0613894B1 (fr) Dérivés de N-heteroaryl-N-phénylurée, leur préparation et utilisation
US6441018B2 (en) Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
EP0261442B1 (fr) Dérivés de l'acide malonique
WO1994013676A1 (fr) Pyrrolopyrimidines en tant qu'antagonistes du facteur liberateur de corticotrophine (crf)
CA2206201A1 (fr) Derives du pyrazole et leur emploi en pharmacie
JPH0623193B2 (ja) 新規なジスタマイシンａ同族体、その製造方法およびそれを含有する医薬組成物
CA2140440A1 (fr) 2-thioindoles (selenoindoles) et disulfides appparentes (selenides) qui inhibent les proteine-tyrosine-kinases et qui ont des proprietes antitumorales
EP2094706B1 (fr) Derives de 2,5-dfflydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues, leur preparation et leur utilisation comme ligands des recepteurs cb1 des cannabinoides
KR960002852B1 (ko) 헤테로아릴 3-옥소-프로판니트릴 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
BE898278A (fr) Benzoxazines antipsychotiques.
CA1184910A (fr) Derives tricycliques de la cytosine utilises contre les troubles circulatoires
US4330472A (en) Meta-sulfonamido-benzamide derivatives
US5721240A (en) 9-substituted-8-unsubstituted-9-deazaguanines
EP1899298B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
HU177338B (en) Process for producing acylamino-heteroaryl compounds
EP1966167B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
US20020058694A1 (en) Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents
WO1993013739A2 (fr) Analogues retroverses d'agents anticancereux a oligopeptides de pyrrole-amidino, leur procede de preparation, et compositions pharmaceutiques contenant ces analogues
WO2000053581A2 (fr) Composes heterocycliques ayant une activite antitumorale
JP3215850B2 (ja) ハロアルコキシ基を含有するピロロ［３，２―ｃ］キノリン誘導体及び薬学的に許容されるその塩
JPH09291076A (ja) 置換グアニジン誘導体およびその製法
US4293713A (en) Novel 1,1,3,5-substituted biuret compound and a pharmaceutical composition containing the same
US6448265B1 (en) Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
FR2911136A1 (fr) Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000920458

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 604021

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09926115

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000920458

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000920458

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)